Pfizer, Merck Beat Estimates on Eliquis, Keytruda Strength
Cover image from cnbc.com, which was analyzed for this article
Pfizer raised revenue guidance on Eliquis strength while Merck posted better-than-expected results driven by Keytruda, though both adjusted profit outlooks due to charges.
PoliticalOS
Tuesday, August 4, 2026 — Business
Both companies cleared revenue estimates on key non-COVID drugs yet booked acquisition charges that altered profit guidance. The results underscore the sector’s reliance on a handful of mature blockbusters while new pipeline bets remain years from material impact.
What outlets missed
The Reuters dispatches on both companies supplied precise product-level breakdowns and consensus comparisons that the CNBC piece lacked. No outlet examined the combined impact of the two firms’ acquisition charges on near-term margins or investor sentiment toward large pharma M&A. Details on the subcutaneous Keytruda formulation’s contribution and Pfizer’s separate $1 billion savings program appeared in only one report each and were not cross-referenced. The tension between raised revenue guidance and lowered adjusted-profit ranges due to one-time items received limited explicit discussion across the coverage.
Pharmaceutical giants Pfizer and Merck both exceeded Wall Street expectations for second-quarter revenue, driven by strong sales of established drugs, yet each adjusted its profit outlook after recording sizable acquisition-related charges. Investors are watching whether these legacy products can sustain growth as COVID-related revenue fades and companies pursue new pipelines in areas such as obesity.
Pfizer reported adjusted earnings of 77 cents per share, above the 68-cent consensus compiled by LSEG, on revenue of $15.03 billion. Eliquis sales reached $2.43 billion, well ahead of the $2.08 billion estimate, while the company raised the lower bound of its full-year revenue guidance to a range of $60.5 billion to $62.5 billion. It simultaneously lowered its COVID-product revenue forecast to $4 billion and recorded a net loss of $248 million after restructuring charges. Merck posted revenue of $16.61 billion, topping the $16.36 billion consensus, with Keytruda sales of $8.37 billion including $463 million from the new subcutaneous formulation. The company raised its 2026 revenue outlook to $66.3 billion–$67.3 billion but reported a 13-cent-per-share loss after a $5.7 billion charge tied to the Terns Pharmaceuticals acquisition.
Both firms highlighted cost-reduction programs and longer-term bets on pipeline assets. Pfizer cited an additional $1 billion in targeted savings through 2029 on top of prior initiatives and pointed to its $10 billion Metsera acquisition. Merck noted double-digit U.S. uptake of Keytruda QLEX and continued Gardasil sales of $1.17 billion. Shares of Pfizer rose 1.8 percent in premarket trading following the results.
More in Business & Economy
Trump Imposes 15% Tariff on Polysilicon to Bolster US Solar, Chip Supply
The administration announced 15% tariffs on polysilicon and derivatives to protect US supply chains and national security. Markets reacted with gains in some solar stocks.
Mortgage Rates Reach One-Year High, Demand Falls
Average 30-year fixed mortgage rates climb for the fourth straight week amid economic data and inflation concerns, reducing demand. Business coverage notes impacts on housing market and consumer spending resilience.
Disney Beats EPS Estimates on Parks, Streaming Gains
Disney beats quarterly estimates driven by parks, streaming gains, and a new TikTok content deal, while exiting stakes in other media. Coverage across business outlets highlights entertainment sector performance.
Caterpillar Raises 2026 Outlook on AI Data Center Orders
Caterpillar beat earnings estimates and lifted its 2026 sales growth target, citing strong demand for data center infrastructure tied to AI expansion.
The Compass
You just read five takes on one story.
What's your take? Find your political shape in a few minutes.
Take the test